Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01282970
First received: January 24, 2011
Last updated: January 11, 2012
Last verified: January 2012
  Purpose

The objective of this study is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 135585 XX following multiple dose administration over 14 days


Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: BI 135585
Drug: Placebo to BI 135585
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses (5 to 100 mg q.d. for 14 Days) of BI 135585 XX in Patients With Type 2 Diabetes Mellitus (Randomized, Double-blind Placebo-controlled Within Dose Groups)

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Safety and tolerability of BI 135585 will be assessed in a descriptive way using physical examinations (occurence of findings), vital signs, electrocardiograms, laboratory tests, and incidence and severity of adverse events. [ Time Frame: up to 16 days post treatment ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Characterization of the pharmacokinetics of BI 135585 in plasma and urine following single and multiple dose oral administration [ Time Frame: up to 10 days post treatment ] [ Designated as safety issue: No ]
  • Exploratory evaluation of the pharmacodynamics of BI 135585 by determination of 11beta-hydroxysteroid dehydrogenase type 1 activity in adipose tissue (ex vivo) [ Time Frame: up to 24 hours post treatment ] [ Designated as safety issue: No ]
  • Exploratory evaluation of the pharmacodynamics of BI 135585 by measuring of cortisol and cortisone and their metabolites in urine [ Time Frame: up to 24 hours post treatment ] [ Designated as safety issue: No ]

Enrollment: 72
Study Start Date: February 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BI 135585
once daily doses as oral solution or tablet formulation over 14 days
Drug: BI 135585
oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
Placebo Comparator: Placebo to BI 135585
once daily doses as oral solution or tablet formulation over 14 days
Drug: Placebo to BI 135585
oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days

  Eligibility

Ages Eligible for Study:   20 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

Type 2 diabetes mellitus, current treatment with no more than one anti-diabetic drug, male or post-menopausal or surgically sterilised female, Body Mass Index 25-40 kg/m2

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01282970

Locations
Germany
1283.2.1 Boehringer Ingelheim Investigational Site
Neuss, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01282970     History of Changes
Other Study ID Numbers: 1283.2, 2010-022698-32
Study First Received: January 24, 2011
Last Updated: January 11, 2012
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on October 29, 2014